Medinet Co

Medinet Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Medinet Co (2370.T) as of Oct 26, 2026 is 3.73. In the previous year, Net Debt to Free Cash Flow Ratio was 3.44 — a change of 8.54% (higher).

Net Debt/FCF

3.73

YoY

8.54%

Last updated:

Net Debt to Free Cash Flow Ratio of Medinet Co is 2024 3.73 . Net Debt to Free Cash Flow Ratio of Medinet Co was 2023 3.44 . It decreases by 8.54% higher compared to the previous year.

The Medinet Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
2.48 JPY
Jan 1, 2018
0.78 JPY
Jan 1, 2019
1.34 JPY
Jan 1, 2020
6.42 JPY
Jan 1, 2021
6.45 JPY
Jan 1, 2022
3.93 JPY
Jan 1, 2023
3.44 JPY
Jan 1, 2024
3.73 JPY
The Medinet Co Net Debt/FCF history
YEARNet Debt/FCFYoY
3.73+8.54%
3.44-12.48%
3.93-39.16%
6.45+0.55%
6.42+378.83%
1.34+70.96%
0.78-68.36%
2.48+7.08%
2.31+99.77%
1.16-65.66%
3.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medinet Co Stock analysis

What does Medinet Co do? MEDINET Co., Ltd. generates revenue through its Cell Processing Industry segment, which offers comprehensive support services for immune cell therapy, including clinical use from companies, universities, and research institutes, outsourcing cell processing for clinical trials, and operating cell culture processing facilities. The Cellular Medical Products segment focuses on research and development to obtain approval for manufacturing and marketing cellular medical products. The company serves clients in the healthcare sector, particularly entities involved in immune cell therapy and cellular medical product development. The Cell Processing Industry segment provides outsourcing services for cell processing in clinical trials, catering to companies, universities, and research institutes seeking specialized processing capabilities. The Cellular Medical Products segment develops cellular medical products requiring regulatory approval, targeting manufacturers and marketers in the medical field. Both segments operate under MEDINET's expertise in cell processing and medical product development. MEDINET's business model relies on delivering specialized cell processing services and supporting the regulatory approval process for cellular medical products. The company's clients include organizations engaged in immune cell therapy research and development, as well as those seeking to commercialize cellular medical products. The dual-segment approach ensures comprehensive coverage of the cell processing and medical product development lifecycle. Medinet Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinet Co stock

Net Debt to Free Cash Flow Ratio of Medinet Co is 3.73 in 2024.

Net Debt to Free Cash Flow Ratio of Medinet Co changed from 3.44 to 3.73, representing a 8.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Medinet Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Medinet Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Medinet Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Medinet Co